Close
Novotech
Jabsco PureFlo 21 Single Use

Aptar Pharma names Jean-Marc Pardonge as prescription division new president

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Lead Selection Impacts CMC Strategy in Drug Development

The molecule you choose to advance into development doesn't just define your science it defines your entire Chemistry, Manufacturing, and Controls roadmap. This article unpacks how early lead selection decisions ripple through CMC planning, regulatory timelines, and ultimately, your path to the clinic.

Integrated Drug Development Consulting for Pharmaceuticals

Strategic oversight and regulatory navigation in the pharmaceutical industry rely on an integrated approach to drug development consulting, ensuring that global clinical pipelines reach the market efficiently.

Inside Cryopreservation: Key Steps and Scientific Insights

It may sound like science fiction to the layperson,...
- Advertisement -

Aptar Pharma, a subsidiary of Aptargroup, has named Jean-Marc Pardonge as the new president for the company’s prescription division.

The company is involved in developing and manufacturing nasal and pulmonary drug delivery devices.

In 2000 Pardonge served as R&D manager for Aptar Pharma’s prescription division and promoted to R&D vice president in 2003.

In January 2010, Pardonge served as global market development president for Aptar Pharma’s prescription division, where he managed and coordinated worldwide activities which included scientific and regulatory affairs, business development, communication, engineering, innovation, marketing, projects and R&D.

The market for prescription division will be leveraged with Pardonge’s knowledge in both the pharmaceutical market and the division’s customers, claims the company.

 

Latest stories

Related stories

How Lead Selection Impacts CMC Strategy in Drug Development

The molecule you choose to advance into development doesn't just define your science it defines your entire Chemistry, Manufacturing, and Controls roadmap. This article unpacks how early lead selection decisions ripple through CMC planning, regulatory timelines, and ultimately, your path to the clinic.

Integrated Drug Development Consulting for Pharmaceuticals

Strategic oversight and regulatory navigation in the pharmaceutical industry rely on an integrated approach to drug development consulting, ensuring that global clinical pipelines reach the market efficiently.

Inside Cryopreservation: Key Steps and Scientific Insights

It may sound like science fiction to the layperson,...

ICON Advarra Partnership Builds Research-Ready Trial Model

ICON, a world-leading clinical research organisation, has formalised a...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »